李芳娟,刘 辉,毛 翎.459例Ⅳ期非小细胞肺癌放疗生存分析[J].肿瘤学杂志,2013,19(6):435-438.
459例Ⅳ期非小细胞肺癌放疗生存分析
Survival Analysis of 459 Cases with Non-small Cell Lung Cancer Stage Ⅳ After Radiotherapy
投稿时间:2013-03-06  
DOI:10.11735/j.issn.1671-170X.2013.06.B006
中文关键词:  肺肿瘤  癌,非小细胞肺  放射疗法  预后
英文关键词:lung neoplasms  carcinoma,non-small cell lung  radiotherapy  prognosis
基金项目:
作者单位
李芳娟 同济大学附属上海市肺科医院 
刘 辉 同济大学附属上海市肺科医院 
毛 翎 同济大学附属上海市肺科医院 
摘要点击次数: 1672
全文下载次数: 1122
中文摘要:
      摘 要:[目的] 分析放疗对于Ⅳ期非小细胞肺癌(NSCLC)患者预后的影响。[方法] 对459例接受放疗的Ⅳ期NSCLC患者资料进行回顾性分析。放疗均采用6/10MV X线直线加速器,全脑和骨放疗为2周10次共30Gy的分割方案。原发灶、区域淋巴结中位放疗剂量为52Gy(25~66Gy)。[结果] 459例患者中位生存期10.7个月。1、2、3、4、5年生存率分别为43%、17%、8%、5%、3%。年龄<70岁较年龄≥70岁的中位生存期长(11.4个月与9.0个月,P=0.043)。单器官转移比多器官转移的中位生存期长(10.9个月与8.6个月,P=0.017)。有无脑转移的中位生存期为9.6个月与11.4个月(P<0.001)。化疗比未化疗的中位生存期长(10.9个月与8.6个月,P=0.011)。原发灶放疗比未行原发灶放疗的中位生存期长(10.9个月与10.3个月,P=0.047)。性别、病理类型对生存未见显著影响。[结论] 年龄、是否脑转移、转移器官数目、是否化疗及是否原发灶放疗对Ⅳ期NSCLC放疗后生存有显著影响。
英文摘要:
      Abstract:[Purpose] To investigate the influence in radiotherapy on prognosis in patients with non-small cell lung cancer(NSCLC) stage Ⅳ.[Methods] Clinical data of 459 patients with NSCLC stage Ⅳ treated with radiotherapy were analyzed retrospectively. Radiotherapy was carried out by linear accelerator(6/10MV X-ray). Whole brain and bone radiotherapy were delivered with a total of 30Gy in 10 fractions for 2 weeks. The median dose for primary tumors and regional lymph nodes was 52Gy(25~66Gy).[Results] The median survival of the 459 patients was 10.7 months. The 1-,2-,3-,4- and 5-year overall survival rates were 43%,17%,8%,5% and 3% respectively.The median survival was longer in the patients <70 years old than that in those ≥70 years old(11.4 months vs 9.0 months,P=0.043),and longer in patients with single organ metastasis than that in patients with multiple organ metastasis(10.9 months vs 8.6 months,P=0.017).The median survival of patients with and without brain metastasis were 9.6 months and 11.4 months respectively(P<0.001).The median survival was longer in the patients with chemotherapy than that in the patients without (10.9 months vs 8.6 months,P=0.011),and longer in the patients with radiotherapy for primary tumors than that in the patients without(10.9 months vs 10.3 months,P=0.047). Gender and pathological types had no significant influence on survival.[Conclusion] Patient’s age,brain metastasis,number of metastatic organ,chemotherapy and radiotherapy for primary tumors may affect the survival in patients with NSCLC stage Ⅳpostradiotherapy.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器